Kidney and liver
Vasopressin V2 receptor antagonists (tolvaptan)
Drugs that block the action of antidiuretic hormone on the collecting duct: tolvaptan slows cyst growth and the decline of kidney function in rapidly progressing polycystic kidney disease, and corrects some hyponatraemia.
Mechanism of action
- Vasopressin acting on V2 receptors raises cyclic AMP in collecting duct cells, inserting aquaporin-2 water channels.
- In polycystic kidney disease, cyclic AMP also drives cyst-lining cells to proliferate and secrete fluid.
- Tolvaptan blocks V2 receptors: free water is excreted (aquaresis) and cyst growth slows.
Molecular targets
- Vasopressin V2 receptor (collecting duct): Antagonist
Drugs in Vasopressin V2 receptor antagonists (tolvaptan)
V2-selective
- Tolvaptan (By mouth; liver tests are monitored.)
V1a and V2
- Conivaptan (Intravenous, V1a and V2; for hyponatraemia.)
Therapeutic uses
- Autosomal dominant polycystic kidney disease at risk of rapid progression
- Hyponatraemia from SIADH or heart failure
Diseases it treats
Adverse effects
- Thirst, frequent urination and nocturia
- Liver injury
- Too rapid a rise in sodium, which can cause osmotic demyelination
Contraindications by condition
- Liver cirrhosis (Contraindicated): Tolvaptan can cause serious liver injury.
- Inability to sense or respond to thirst (Contraindicated): Free water loss causes dehydration and hypernatraemia.
- Taking strong CYP3A4 inhibitors (Use with care): Levels rise sharply.
Connected topics
Written from
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 15, Diuretic Agents, ADH antagonists
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 37, Hypothalamic & Pituitary Hormones, Vasopressin antagonists
Educational reference. Not medical advice, diagnosis or treatment.